Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele, Shuai Li, Kai Wen Teng, et al.
The Journal of Experimental Medicine (2020) Vol. 218, Iss. 1
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 600
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Noritaka Tanaka, W. Marston Linehan, Chendi Li, et al.
Cancer Discovery (2021) Vol. 11, Iss. 8, pp. 1913-1922
Open Access | Times Cited: 372
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 306
The metabolic landscape of RAS-driven cancers from biology to therapy
Suman Mukhopadhyay, Matthew G. Vander Heiden, Frank McCormick
Nature Cancer (2021) Vol. 2, Iss. 3, pp. 271-283
Open Access | Times Cited: 198
The potential role of N7-methylguanosine (m7G) in cancer
Yuejun Luo, Yuxin Yao, Peng Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 170
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 132
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 130
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Jun Tian, Jonathan H. Chen, Sherry Chao, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 458-466
Open Access | Times Cited: 108
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 92
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 90
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Meagan B. Ryan, Oluwadara Coker, Alexey V. Sorokin, et al.
Cell Reports (2022) Vol. 39, Iss. 12, pp. 110993-110993
Open Access | Times Cited: 89
A comprehensive review of SHP2 and its role in cancer
Moges Dessale Asmamaw, Xiaojing Shi, Lirong Zhang, et al.
Cellular Oncology (2022) Vol. 45, Iss. 5, pp. 729-753
Closed Access | Times Cited: 74
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 72
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
Stephanie M. Stanford, Nunzio Bottini
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 4, pp. 273-294
Open Access | Times Cited: 70
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 48
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Mı́riam Molina-Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 48
Next batter up! Targeting cancers with KRAS-G12D mutations
Mara N. Zeissig, Lauren M. Ashwood, Olga Kondrashova, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 955-967
Open Access | Times Cited: 43
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 42
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Junli Lu, Yiming Luo, Dean Rao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 39
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 36
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 28
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 27
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Yuchu Xiang, Xudong Liu, Yifan Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 23
Mechanisms of Resistance to KRASG12C Inhibitors
Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall, et al.
Cancers (2021) Vol. 13, Iss. 1, pp. 151-151
Open Access | Times Cited: 101
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr, Franziska Haderk, Trever G. Bivona
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 1-12
Closed Access | Times Cited: 100
Page 1 - Next Page

Scroll to top